Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11369144 | 0.83 | CA1 (0.31) | — | |
| SCHEMBL7637933 | 0.74 | — | — | |
| SCHEMBL4495654 | 0.73 | KDM4E (0.30) | LMNA | |
| SCHEMBL19663105 | 0.70 | — | — | |
| SCHEMBL7639189 | 0.70 | — | — | |
| SCHEMBL599372 | 0.68 | LMNA (0.39) | LMNA | |
| SCHEMBL37684 | 0.67 | — | — | |
| SCHEMBL19662312 | 0.65 | — | — | |
| SCHEMBL9303678 | 0.65 | ALDH1A1 (0.38) | LMNA | |
| Hydrochloric Acid SCHEMBL29430077 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758088-B1 | SURGICAL BARRIER POSSESSING CLINICALLY IMPORTANT ABSORPTION CHARACTERISTICS | BVW HOLDING AG (CH) | 2024-01-10 | — | — | EP | claimed |
| CN-107207696-B | Biodegradable polymers | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2023-05-23 | — | — | CN | claimed |
| US-20170369628-A1 | BIODEGRADABLE POLYMER | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2017-12-28 | — | — | US | claimed |
| EP-3240819-A1 | BIODEGRADABLE POLYMER | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-11-08 | — | — | EP | claimed |
| WO-2016108242-A1 | BIODEGRADABLE POLYMER | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-07-07 | — | — | WO | claimed |
| US-7879356-B2 | AB block polymers, comprising a polylactone part made from monomers such as lactic acid, and B is derived from hydroxyl, amine, or carboxyl terminated compound endcapped with nonreactive group; storage stablity; anti-adhesions | SYNTHEMED, INC. (US) | 2011-02-01 | — | — | US | claimed |
| US-7569643-B2 | Reverse thermal gellation polymer of chain-extended optional polyester-terminated PEO-PPO-PEO | SYNTHEMED, INC. (US) | 2009-08-04 | — | — | US | claimed |
| WO-2008074564-A2 | NOVEL DISPERSING RESINS, PRODUCTION THEREOF, AND USE THEREOF FOR DISPERSING SOLIDS | EVONIK GOLDSCHMIDT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| EP-0939639-B1 | METHODS AND COMPOSITIONS FOR REDUCING OR ELIMINATING POST-SURGICAL ADHESION FORMATION | LIFE MEDICAL SCIENCES INC (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050095302-A1 | Novel polymeric compositions exhibiting reverse thermal gellation properties | PATHFINDER CELL THERAPY, INC. | 2005-05-05 | — | — | US | claimed |
| US-20010009662-A1 | Novel polymeric compositions | LIFE MEDICAL SCIENCES, INC. | 2001-07-26 | — | — | US | claimed |
| EP-1014998-A4 | POLYMERIC COMPOSITIONS | LIFE MEDICAL SCIENCES INC (US) | 2000-10-25 | — | — | EP | claimed |
| US-6136333-A | BY EXPOSING TISSUE TO CHAIN EXTENDED, COUPLED OR CROSSLINKED POLYLACTONE-POLYOXYALKYLENE GLYCOL TRIBLOCK OR DIBLOCK HAVING GIVEN ETHYLENE OXIDE:LACTOYL(ESTER) RATIO, WHICH PROVIDES A BARRIER TO PREVENT OR REDUCE THE EXTENT OF ADHESIONS FORMING | LIFE MEDICAL SCIENCES, INC. (US) | 2000-10-24 | — | — | US | claimed |
| EP-1014998-A1 | POLYMERIC COMPOSITIONS | LIFE MEDICAL SCIENCES, INC. (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0636639-B1 | Copolymers of an aromatic anhydride and aliphatic ester | ETHICON INC (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0939639-A1 | METHODS AND COMPOSITIONS FOR REDUCING OR ELIMINATING POST-SURGICAL ADHESION FORMATION | LIFE MEDICAL SCIENCES, INC. (US) | 1999-09-08 | — | — | EP | claimed |
| WO-1999002168-A1 | NOVEL POLYMERIC COMPOSITIONS | LIFE MEDICAL SCIENCES INCORPORATED (US) | 1999-01-21 | — | — | WO | claimed |
| WO-1998002171-A1 | METHODS AND COMPOSITIONS FOR REDUCING OR ELIMINATING POST-SURGICAL ADHESION FORMATION | LIFE MEDICAL SCIENCES, INC. (US) | 1998-01-22 | — | — | WO | claimed |
| EP-0636639-A1 | Copolymers of an aromatic anhydride and aliphatic ester | ETHICON, INC. (US) | 1995-02-01 | — | — | EP | claimed |
| US-5321113-A | Biomedical polymer | ETHICON, INC. (US) | 1994-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009662-A1 | Novel polymeric compositions | BAG3, BAG2, BSG | LMNA 4723/4885CYP2C9 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.